<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093349</url>
  </required_header>
  <id_info>
    <org_study_id>SPK-3006-101</org_study_id>
    <secondary_id>2019-001283-30</secondary_id>
    <nct_id>NCT04093349</nct_id>
  </id_info>
  <brief_title>A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)</brief_title>
  <official_title>Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single&#xD;
      intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease&#xD;
      receiving enzyme replacement therapy (ERT). Participants will be treated in sequential,&#xD;
      dose-level cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse and serious adverse events (AEs/SAEs), including clinically significant abnormal laboratory values.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of immune response against AAV capsid</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of immune response against GAA transgene</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pompe Disease</condition>
  <condition>Pompe Disease (Late-onset)</condition>
  <condition>Glycogen Storage Disease Type 2</condition>
  <condition>Glycogen Storage Disease Type II</condition>
  <condition>LOPD</condition>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Acid Maltase Deficiency</condition>
  <arm_group>
    <arm_group_label>SPK-3006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SPK-3006</intervention_name>
    <description>adeno-associated viral (AAV) vector</description>
    <arm_group_label>SPK-3006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Males and Females ≥18 years of age with late-onset Pompe disease;&#xD;
&#xD;
          -  Received ERT for at least the previous 24 months&#xD;
&#xD;
          -  Have clinically moderate, late-onset Pompe disease characteristics;&#xD;
&#xD;
          -  Agree to use reliable contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active hepatitis B and/or C;&#xD;
&#xD;
          -  Significant underlying liver disease;&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Prior hypersensitivity to rhGAA;&#xD;
&#xD;
          -  Pre-existing anti-AAV neutralizing antibody titers;&#xD;
&#xD;
          -  High titer antibody responses to rhGAA;&#xD;
&#xD;
          -  Requires any invasive ventilation or requires noninvasive ventilation while awake and&#xD;
             upright;&#xD;
&#xD;
          -  Received any prior vector or gene transfer agent;&#xD;
&#xD;
          -  Active malignancy (except non-melanoma skin cancer);&#xD;
&#xD;
          -  History of liver cancer;&#xD;
&#xD;
          -  Pregnant or nursing women;&#xD;
&#xD;
          -  Any evidence of active infection at the time of SPK-3006 infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahseen Mozaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Irvine Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Director</last_name>
    <phone>+1 215-220-9300</phone>
    <email>Resolute@sparktx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shafeeq Ladha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahseen Mozaffar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazen Dimachkie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chester Whitely, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chafic Karam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Clemens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>84 2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Vissing, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Paris IdF Ouest - Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Laforet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13 13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shahram Attarian, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>6000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina Sacconi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Friedrich-Baur-Institut Neurologische Klinik Ludwig-Maximilians-Universität München</name>
      <address>
        <city>Munchen</city>
        <zip>D08033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benedikt Schoser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Messina - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Messina</city>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Toscano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Milano, Laboratorio di Biochimica e Genetica della Malattie Neuromuscolari</name>
      <address>
        <city>Milano</city>
        <zip>35 20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Comi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malattie Metaboliche Universita Degli Studi Di Napoli Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giancarlo Parenti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UO Neurologia Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Siciliano, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino - Neurology, Osp. Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiziana Mongini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ans van der Ploeg, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago/Fundacion Investigacion, Desenvolvemento e Innovacion Ramon Dominguez</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Luz Couce Pico, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Paradas Lopez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal MHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Roberts, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://resolutestudy.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

